Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The effect of HIV infection on the clinicopathological characteristics of diffuse large B-cell lymphoma (DLBCL) remains debatable. Methods: Fifty-three HIV-infected and ninety-three HIV-uninfected DLBCL patients were enrolled in the retrospective study by propensity score matching for sex, age, body mass index and international prognostic index (IPI) at a ratio of 1:2. The clinicopathological characteristics were compared between the two groups. Results: HIV-infected DLBCL patients had lower white blood cell counts [×109/L; 4.4 (3.4−5.6) vs. 6.1 (4.2−8.2), p < 0.001], platelet counts (×109/L; 184.7 ± 89.3 vs. 230.0 ± 113.9, p = 0.014) and serum albumin (g/L; 37.3 ± 6.9 vs. 41.3 ± 6.2, p < 0.001) but higher incidences of central nervous system (CNS) involvement (9.4% vs. 1.1%, p = 0.014), bone marrow involvement (24.5% vs. 11.5%, p = 0.044) and Epstein−Barr viremia (61.1% vs. 26.7%, p = 0.002) than HIV-uninfected patients. In terms of histopathology, HIV-infected patients had higher positivity of Epstein−Barr virus-encoded small RNA (EBER) (41.7% vs. 6.7%, p = 0.002), but lower CD20 (90.2% vs. 98.7%, p= 0.029) and CD79a (23.1% vs. 53.7%, p < 0.001) expression. The overall response rate (ORR) at the end of chemotherapy (70.2% vs. 87.8%, p= 0.012) and 1-year overall survival (OS) (61.7% vs. 84.2%, log-rank p = 0.006) in HIV-infected patients were significantly lower than those in HIV-uninfected patients. Multivariate analysis suggested IPI ≤2.0 [adjusted odds ratio (AOR) (95% confidence interval): 5.0 (1.2−21.2), p = 0.030] was associated with ORR, hypoalbuminemia [AOR: 3.3 (1.3−9.1), p = 0.018] and CNS involvement [AOR: 3.3 (1.0−10.5), p = 0.044] were associated with reduced 1-year OS in HIV-infected patients. Conclusion: HIV-infected DLBCL patients have unique blood profiles and phenotypic markers. Low ORR and 1-year OS were observed in HIV-infected DLBCL patients in our study, even in the HAART era.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655449 | PMC |
| http://dx.doi.org/10.3390/cancers14215380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma.
Transplant Cell Ther
September 2025
H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Background: ZUMA-7 is the largest randomized controlled trial (RCT) for chimeric antigen receptor (CAR) T-cell therapy, which compared axicabtagene ciloleucel (axi-cel) to historical standard of care (HSoC) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Both arms of ZUMA-7 contained potentially curative treatments; however, differences in the treatment completion rate and timing to receive definitive treatment led to differences in the extent and timing of cure. Mixture cure modeling (MCM) has been suggested as a superior method in designing and powering clinical studies of curative therapies but also for extrapolation of long-term outcomes in simulation studies.
View Article and Find Full Text PDFAn international prognostic index to predict the early chemoimmunotherapy failure of diffuse large B-cell lymphoma.
Ann Hematol
September 2025
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Approximately 30-40% of diffuse large B-cell lymphoma (DLBCL) patients will develop relapse/refractory disease, who may benefit from novel therapies, such as CAR-T cell therapy. Thus, accurate identification of individuals at high risk of early chemoimmunotherapy failure (ECF) is crucial. Methods.
View Article and Find Full Text PDFThe effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.
Blood Cell Ther
August 2025
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory non-Hodgkin lymphoma, achieving a 5-year overall survival rate of 40-50%. However, relapse remains a major challenge, especially due to CD19-negative clones. Epcoritamab, a bispecific antibody targeting CD20 and CD3, offers a potential solution for post-CAR-T relapse; however, clinical data in this setting remain limited, particularly in Japan.
View Article and Find Full Text PDFComparative Evaluation of Response in Diffuse Large B-cell Lymphoma Using Ga-Pentixafor PET/CT and F-FDG PET/CT.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive type of non-Hodgkin lymphoma. Accurate evaluation of treatment response is essential for effective management. This case report discusses the potential role of ⁶⁸Ga-Pentixafor positron emission tomography (PET)/computed tomography (CT) in comparison to F-fluorodeoxyglucose PET/CT for assessing treatment response in a patient with DLBCL.
View Article and Find Full Text PDFPrimary bladder diffuse large B-cell lymphoma: A rare case report.
Int J Surg Case Rep
September 2025
Department of Urology, The Second Affiliated Hospital, Kunming Medical University, Yunnan Province, China. Electronic address:
Introduction: Diffuse large B-cell lymphoma (DLBCL), a common subtype of non-Hodgkin lymphoma (NHL), originates primarily from lymph nodes, with a small proportion arising extranodally in sites such as the gastrointestinal tract and central nervous system. Given the general absence of lymphoid tissue in the bladder, primary bladder DLBCL is exceptionally rare.
Case Presentation: This case report describes an 83-year-old male patient with a bladder mass, initially suspected as cystitis glandularis, ultimately diagnosed via pathological examination as DLBCL.